BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

BioForm Inc. Announces Extension of Lock-Up Period


5/7/2008 11:28:36 AM

SAN MATEO, Calif., May 5 /PRNewswire-FirstCall/ -- BioForm Medical, Inc. announced today that lock-up agreements entered into with its underwriters in conjunction with its initial public offering will be extended 18 days beyond the Company's May 1, 2008 earnings release. The lock-up period was due to expire on May 3, but the Company's underwriting agreement provided for an extension, depending on the timing of BioForm Medical's quarterly earnings press release. The first sales of shares restricted by the underwriter's lock-up may take place on Tuesday, May 20, 2008. Approximately 33 million shares will become eligible for sale in the public market upon expiration of the underwriters' lock-up, of which approximately 10 million shares will be freely tradable under Rule 144(b) and the remainder will be held by affiliates and other stockholders subject to the volume and other restrictions of Rule 144.

An additional number of shares equal to less than 5.0% of the shares outstanding prior to the November 2007 initial public offering were either not subject to a lock-up agreement or were subject to a lock-up agreement with the Company, the terms of which were less restrictive than the lock-up agreement with the underwriters, and, as such, became freely tradeable on May 5, 2008.

About BioForm Medical, Inc.:

BioForm Medical, Inc. is a medical aesthetics company headquartered in San Mateo, California, developing products that enhance aesthetic procedures performed in dermatology and plastic surgery practices. BioForm's lead product is Radiesse(R), a long-lasting dermal filler for use in facial aesthetics. BioForm is developing several future aesthetics products including a nerve ablation device for frown lines, a sclerotherapy treatment for spider veins, and a surgical adhesive for brow lifts.

CONTACT: Adam Gridley, Vice President, Corporate Development of BioForm
Medical, Inc., +1-650-286-4025

Web site: http://www.bioformmedical.com//



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES